Medical Writing Generics and biosimilars Biosimilars: Change, challenge, and accomplishments
mew-generics-and-biosimilarspng

Volume 28, Issue 2 - Generics and biosimilars

Biosimilars: Change, challenge, and accomplishments

Abstract

Since the first biosimilar product was approved in Europe in 2006, there have been many developments in the global regulatory environment, and the healthcare community’s understanding and acceptance of biosimilars. However, there are still a number of challenges in developing, registering, and marketing biosimilar medicines, with the ultimate objective always being to increase competition, drive down costs, and increase access to biologic medicines. This article examines progress to date in the establishment of the biosimilar market, challenges in bringing biosimilars to patients, the impact biosimilars have had, and potential future trends.

Download the full article

References

  1. World Health Organization. Guidelines on evaluation of similar Biotherapeutic Products (SBPs), Annex 2, Technical Report Series No. 977, 2009 [cited 2019 Mar 10]. Available from: Available from: https://www.who.int/biologicals/ biotherapeutics/similar_biotherapeutic_ products/en/.
  2. European Medicines Agency. Guideline on similar biological medicinal products, CHMP/437/04 Rev 1 [cited 2019 Mar 10]. Available from: Available from: https://www.ema.europa.eu/en/document s/scientific-guideline/guideline-similarbiological- medicinal-products-rev1_en.pdf.
  3. Sarpatwari A, Barenie R, Curfman G, Darrow JJ, Kesselhein AS. The US Biosimilar Market: Stunted Growth and Possible Reforms. Am Soc Clin Pharmacol and Ther. 2019;105(1):92–100
  4. Curto A. Trends and challenges in bio - similars pricing and reimbursement policies in Europe and beyond. Generics and Biosimilars Initiative J. 2017;6(2): 56–7
  5. European Medicines Agency. Medicines [cited 2019 Mar 10]. Available from: Available from: https://www.ema.europa.eu/en/ medicines.
  6. U. S. Food & Drug Administration (FDA). Biosimilar Product Information [cited 2019 Mar 10]. Available from: Available from: https://www.fda.gov/drugs/ developmentapprovalprocess/ howdrugsaredevelopedandapproved/ approvalapplications/therapeuticbiologic applications/biosimilars/ucm580432.htm.
  7. Generics and Biosimilars Initiative Online. Guidelines for biosimilars around the world, posted 13 April 2018 [cited 2019 Mar 10]. Available from: Available from: http://www.gabionline.net/Reports/ Guidelines-for-biosimilars-around-theworld.
  8. Generics and Biosimilars Initiative Online. Biosimilars in emerging markets, posted 19 Sept 2014 [cited 2019 Mar 10]. Available from: Available from: http://www.gabionline. net/Reports/ Biosimilars-in-emergingmarkets.
  9. QuintilesIMS. The impact of biosimilar competition in Europe, published 5 May 2017 [cited 2019 Mar 10]. Available from: Available from: https://ec.europa.eu/ growth/content/ impact-biosimilar-competition-price-volumeand- market-share-update-2017–0_en.
  10. European Medicines Agency. Neulasta: EPAR – Product Information. 2018.
  11. Roche. MabThera SC/Rituxan Hycela™ (rituximab/hyaluronidase human) [cited 2019 Mar 14]. Available from: Available from: https://www.roche.com/products/ product-details.htm?productId=8abc3f49- f39f-4c6e-93ae-235c95c7efc6.
  12. Tesser JRP, Furst DE, Jacobs I. Biosimilars and the extrapolation of indications for inflammatory conditions. Biologics. 2017;11:5–11.
  13. U. S. Food & Drug Administration (FDA). Considerations in Demonstrating Interchangeability With a Reference Product, Draft Guidance, January 2017 [cited 2019 Mar 10]. Available from: Available from: https://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/UCM537135.pdf.
  14. U. S. Food & Drug Administration (FDA). Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations, [cited 2019 Mar 10]. Available from: Available from: https://www.fda.gov/drugs/development approvalprocess/howdrugsaredeveloped andapproved/approvalapplications/ therapeuticbiologic applications/ biosimilars/ucm411418.htm.
  15. U. S. Food & Drug Administration (FDA). Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s steps on naming of biological medicines to balance competition and safety for patients receiving these products, 7 March 2019 [cited 2019 Mar 10]. Available from: Available from: https://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ ucm632870.htm.

Search

Articles

Introduction
James Visanji Tribute
President’s Message
EMWA News
Regulatory pathways for development and submission activities
Biosimilar development – an overview
Statistical principles in biosimilar development
Writing biosimilar clinical study reports and submission documents – what to expect and what to consider
Medical writing for generics throughout the life cycle
Same but different: Basic tools for biosimilar and generic pharmacovigilance writing
Layperson materials in the sphere of biosimilars and generic medicines
Insulin biosimilars
Biosimilars: Change, challenge, and accomplishments
ICMJE requirements for sharing individual participant data from interventional clinical trials
Medicinal products and medical devices in clinical trials conduct and disclosure
Publication of clinical trial protocols and statistical analysis plans on ClinicalTrials.gov
Collecting metrics in medical writing – the benefits to you and your business
Document management systems for medical writing
Winner of the Geoff Hall Scholarship Essay Competition
Regulatory Matters
News from the EMA
Getting Your Foot in the Door
Veterinary Medical Writing
Teaching Medical Writing
Medical Devices
My First Medical Writing
Journal Watch
Good Writing Practice
Regulatory Public Disclosure
Out on Our Own

Member Login

Links

The Write Stuff Archive Contact Instructions for Authors Feature Article Template (Word) Journal Policies

Editoral Board

Editor-in-Chief:

Co-Editor:

Managing Editor

show all +

Associate Editors:

Section Editors:

Ad-hoc Editors:

  • Amy Whereat (SpeaktheSpeech Consulting, Asnieres sur Seine, France)

Editor Emeritus: